VALN logo

VALN
Valneva SE - ADR

2,113
Mkt Cap
$531.75M
Volume
13,504.00
52W High
$12.25
52W Low
$5.43
PE Ratio
-3.97
VALN Fundamentals
Price
$6.18
Prev Close
$6.15
Open
$6.22
50D MA
$9.26
Beta
0.87
Avg. Volume
119,896.74
EPS (Annual)
-$1.55
P/B
4.30
Rev/Employee
$292,457.41
$856.29
Loading...
Loading...
News
all
press releases
Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why
Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...
PR Newswire·3d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...
PR Newswire·10d ago
News Placeholder
Valneva (NASDAQ:VALN) Shares Gap Up - Should You Buy?
Valneva (NASDAQ:VALN) Shares Gap Up - What's Next...
MarketBeat·11d ago
News Placeholder
Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why
Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - What's Next...
MarketBeat·13d ago
News Placeholder
Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Rises By 25.4%
Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) saw a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 173,642 shares, a growth of 25.4% from the February 26th total of 138,488 shares. Approximately 0.2% of the company's shares are...
MarketBeat·14d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...
PR Newswire·17d ago
News Placeholder
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
Valneva plunges 37% as Lyme vaccine study shows 70%+ efficacy but misses key statistical target, raising concerns despite plans for regulatory filings.
Zacks·19d ago
News Placeholder
Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Still a Buy...
MarketBeat·20d ago
News Placeholder
Pfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial
(RTTNews) - Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: in the pre-specified analyses...
Nasdaq News: Markets·21d ago
<
1
2
...
>

Latest VALN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.